Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Home
/
update
/
details

AIIMS Partners with Wipro GE Healthcare to Launch AI Health Innovations Hub

NextEdge Admin

15 Dec 2024

2 min 36 sec

All India Institute of Medical Sciences,AI,MedTech

The All India Institute of Medical Sciences (AIIMS), New Delhi, has partnered with Wipro GE Healthcare Pvt Ltd to establish an AI Health Innovations Hub. This initiative aims to transform healthcare delivery by developing AI-powered solutions for precise diagnosis, innovative treatments, and real-time patient monitoring, focusing on cardiology, oncology, and neurology.

Wipro GE Healthcare will invest $1 million over five years to co-develop, test, and deploy intelligent systems. As the clinical partner, AIIMS will provide multimodal clinical expertise and serve as a real-world testing environment. A joint working committee will oversee the collaboration, fostering clinical research and academic engagement.

The National AI Portal of India (INDIAai) highlights AI's potential to boost the GDP by $25–30 billion by 2025 through enhanced healthcare delivery. By integrating longitudinal patient data—such as imaging, lab results, and medical records—with analytics, AI can revolutionize diagnosis, operations, and patient care.

Dr. M. Srinivas, Director of AIIMS, emphasized the strategic alignment of this collaboration with India's vision for advanced healthcare, underscoring AIIMS' commitment to advancing clinical research and improving patient outcomes.

Parminder Bhatia, Chief AI Officer at GE HealthCare, described AI as a transformative force to democratize healthcare and enable predictive, preventive, and personalized care. Chaitanya Sarawate, Managing Director, Wipro GE Healthcare South Asia, called the partnership a significant step towards developing AI-based models for clinical care in India and beyond.

AIIMS, India’s premier medical institute, is renowned for high-standard medical education and research. Wipro GE Healthcare, a leading MedTech player, combines expertise from GE Precision Healthcare and Wipro Enterprises to advance healthcare innovation across South Asia.